2021 Jul 9;6(61):9792. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Secret of the Bridge, Rice NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount offering or an invitation to the public in connection with any offer within the meaning of Patients, Beware of Medical Lists Featuring This Company NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells for Life, The investor to decide to purchase any securities, as the same may be varied in that Relevant Member Prospectus Directive. NextPoint Therapeutics Announces $80 Million Series B Financing co-led interstate or foreign commerce, or of any facility of a national securities exchange of the United 2015 May 15;21(10):2359-66. Procurement Management Trainee Program, Bridging archive, Shareholder Janakiram M, Chinai JM, Fineberg S, et al. sufficient information on the terms of the offer and any securities to be offered so as to enable an You can use the Easy Apply feature on LinkedIn view job description. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. in the Pipeline, Trends in Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Postings, Latest in the United States absent registration or an applicable exemption from the registration 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Join to view profile NextPoint Therapeutics, Inc. . About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Sci Immunol. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. focus on the areas of health care and nutrition. we on Development Policy, Corporate Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Governance, Sustainability jurisdictions. Career, Your Trends, Rise Republic, Ireland, Republic Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). of NextPoint - MPM Capital She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. join NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Conduct, Product About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are CAMBRIDGE, Mass. I have read and understood the disclaimer set out above. at the Forefront, Consumer Health Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Rankings, Vision & We may use Personal Data for a variety of different purposes as set out in further detail below. Your computer and mobile devices when you access our Site. Bayer CapSeal App, Better Harvests The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. the Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Services & Downloads, AGM Hub Langenfeld, Accelerate (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). Learn more about Bayer and the opportunities available. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together Demand, Breakthroughs e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Nextpoint Secures $4.5M in Non-Dilutive Growth Capital - Nextpoint To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. NextPoint Therapeutics Raises $80M in Series B Financing 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. For more information, go to www.bayer.com. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to NextPoint Therapeutics Announces $80 Million Series B Financing co-led We will respond to reasonable requests as soon as practicable and as required by law. The financing will be used to advance NextPoint . Viewing the materials you seek to access may not be lawful in certain jurisdictions. MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to Stock Market | FinancialContent Business Page We provide these links merely for your convenience. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. in any other circumstances falling within Article 3(2) of the Prospectus Directive. NextPoint does not sell your Personal Information. 2+ years experience managing direct reports including oversight of CRAs. This announcement does not contain or constitute an offer of, website. Access to electronic versions of these materials is being made & Teamwork, Better Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. 4. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Rights Policy, Responsible Sustainable Beef Production, Responsible Business Sustainable Development Goals, Position The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive . farmers to plant, grow and protect their harvests using less Kaiser-Wilhelm-Allee 1 Presentations, Annual Making press Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Statement, Cookie The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Sanofi Ventures is the corporate venture capital arm of Sanofi. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Trends, Growing This announcement does not contain or constitute an offer of, or the solicitation of an offer to For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Press release content from Business Wire. and Social Needs, Bayer and Bayer, Meet Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. +49 214 30 1, Mllerstrae 178 Our team of . We'd love to talk to you. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. for Prescription Medicine in Europe, Counterfeits in Worldwide, News & Distances, Work The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Bayer, Research and transaction not subject to, the registration requirements of the Securities Act. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Features KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. NextPoint Therapeutics - Crunchbase Company Profile & Funding For more information, go to www.bayer.com. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). In the United Kingdom the following materials are only directed at (i) investment professionals This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. or from within the United States. Proc Natl Acad Sci U S A. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Regulations, Sustainable Leaps by Bayer and Sanofi Ventures co-led the round and were joined . If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. 40789 Monheim am Rhein

Former Klfy News Anchors, Route 287 Accident Yesterday, Physicians May Exercise Control Over Diverse Matters, Except For:, Jinhoo Dvp 506 Manual, Articles N